HRID1945961

反应详情

EQUATION

反应方程式

REACTANTS

反应物

HCID1084419

2-cyclopropyl-1H-benzimidazole

C10H10N2

结构：Cn1c(CN2CCN(C(C)(C)C(N)=O)CC2)nc2c(N3CCOCC3)nc(Cl)nc21

HCID58439189

4-[[2-Chloro-9-methyl-6-(4-morpholinyl)-9H-purin-8-yl]methyl]-α,α-dimethyl-1-piperazineacetamide

C19H29ClN8O2

PRODUCTS

生成物

结构：Cn1c(CN2CCN(C(C)(C)C(N)=O)CC2)nc2c(N3CCOCC3)nc(-n3c(C4CC4)nc4ccccc43)nc21

HCID59605487

未命名化合物

PROCEDURE

实验过程

2-(4-((2-Chloro-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-1-yl)-2-methylpropanamide (75 mg) was reacted with 2-cyclopropylbenzimidazole via General Procedure I for Buchwald coupling to give 38.7 mg 438 following reverse phase purification. MS (Q1) 559.1 (M)+

WORKUP

后处理

customto give
custom38.7 mg 438 following reverse phase purification

来源与证据

来源类型: Open Reaction Database
ORD 记录: ord-b3f2e2db968c40d28f29f2adb73232be
来源数据集: uspto-grants-2013_03
DOI: 10.6084/m9.figshare.5104873.v1
专利: US08394796B2
来源说明: uspto-grants-2013_03

反应 SMILES

Cl[C:2]1[N:10]=[C:9]2[C:5]([N:6]=[C:7]([CH2:12][N:13]3[CH2:18][CH2:17][N:16]([C:19]([CH3:24])([CH3:23])[C:20]([NH2:22])=[O:21])[CH2:15][CH2:14]3)[N:8]2[CH3:11])=[C:4]([N:25]2[CH2:30][CH2:29][O:28][CH2:27][CH2:26]2)[N:3]=1.[CH:31]1([C:34]2[NH:35][C:36]3[CH:42]=[CH:41][CH:40]=[CH:39][C:37]=3[N:38]=2)[CH2:33][CH2:32]1>>[CH:31]1([C:34]2[N:35]([C:2]3[N:10]=[C:9]4[C:5]([N:6]=[C:7]([CH2:12][N:13]5[CH2:18][CH2:17][N:16]([C:19]([CH3:24])([CH3:23])[C:20]([NH2:22])=[O:21])[CH2:15][CH2:14]5)[N:8]4[CH3:11])=[C:4]([N:25]4[CH2:26][CH2:27][O:28][CH2:29][CH2:30]4)[N:3]=3)[C:36]3[CH:42]=[CH:41][CH:40]=[CH:39][C:37]=3[N:38]=2)[CH2:33][CH2:32]1